U.S. Sees Vaccines Meeting Demand as J&J Halt Adds Rollout Risk
(Bloomberg) -- The U.S. expects to have enough coronavirus vaccine to meet demand by May even with a pause in the use of Johnson & Johnson’s shot -- but a lengthy halt would upend some of President Joe Biden’s goals and prolong the effort to inoculate as many Americans as possible.
The U.S. Centers for Disease Control and Prevention and Food and Drug Administration said on Tuesday in a joint statement that they would pause use of the J&J shot after six women who received it developed a rare and severe form of blood clotting. The FDA signaled the pause would last a matter of days.
The sidelining of J&J, however temporary, leaves the U.S. with two other shots that already made up the bulk of its vaccination campaign --- from Pfizer Inc. and Moderna Inc. Vaccines from those two companies account for 95% of the shots allocated in the U.S. this week.
The White House said there’s enough vaccine to continue giving shots at their current pace. “This announcement will not have a significant impact on our vaccination plan,” said Jeff Zients, the White House Covid-19 response coordinator, in a statement.
https://www.msn.com/en-us/money/markets/us-sees-vaccines-meeting-demand-as-jandj-halt-adds-rollout-risk/ar-BB1fBPjJ
